ArticleCaspian journal of internal medicine2026
Gastric cancer patients' survival with neoadjuvant chemotherapy versus direct surgery.
Article in Caspian journal of internal medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Despite these theoretical advantages, there is still a lack of evidence to answer whether NeoAdjuvant Chemotherapy (NAC) can further improve the survival of Locally Advanced Gastric Cancer (LAGC) patients on the basis of Adjuvant Chemotherapy (AC) following curative gastrectomy. The present research assessed the 36-month survival of gastric cancer patients treated in our center with and without NAC and over-all 36-month survival. Methods: The present research assessed the 36-month survival of gastric cancer patients treated in our center with and without NAC and over-all 36-month survival. 79 patients entered this study, of whom 64 received NAC and 15 underwent direct surgery. Results: Generally, the three-year survival rate in the groups was statistically different based on the Wilcoxon test (P 0.004). NAC was effective in increasing survival in the groups with lymph o vascular invasion, higher stage and all pathologic groups. However, age, type of surgery (TG vs DG), number of positive lymph nodes, and positive margin after surgery were not effective in interfering with survival in both groups. Neoadjuvant chemotherapy can positively increase OS and DFS in locally advanced gastric cancer. NAC was effective in increasing survival in the groups with lymph o vascular invasion, higher stage and all pathologic groups. Conclusion: Considering the similar results in previous studies, larger prospective studies with accurate information can effectively achieve definitive results. However, age, type of surgery (TG vs DG), number of positive lymph nodes, positive margin after surgery were not effective interfering with survival in both groups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.